文献速递食管胃疾病与幽门螺杆菌

随机对照试验:药敏指导疗法与经验性铋剂四联疗法用于幽门螺杆菌一线治疗的比较

Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
PubMed 文献 · Aliment Pharmacol Ther · 2019-04-24

在抗菌药物耐药高发地区,多中心优效性设计随机对照试验将382例幽门螺杆菌感染者按3:1随机分配至14天药敏指导疗法或经验性改良铋剂四联疗法。按方案分析根除率分别为97.7%(250/256)与97.6%(81/83,P=1.00),意向性分析为91.6%(262/286)与85.4%(82/96,P=0.12),药敏指导疗法未优于经验性疗法。

要点

  • 药敏指导疗法按方案根除率97.7%(250/256),经验性疗法97.6%(81/83),P=1.00。
  • 意向性分析根除率药敏指导组91.6%(262/286),经验性组85.4%(82/96),P=0.12。
  • 药敏指导疗法未优于经验性疗法,按方案差异0.1%(95%CI -3.1%至3.2%)。

核心结论

  • 药敏指导疗法和经验性疗法均提供极佳的根除率。
  • 临床上,选择取决于药敏检测的可及性和/或当地高度有效的经验性疗法。

研究设计与样本

  • 多中心优效性设计随机对照试验,将幽门螺杆菌感染受试者按3:1随机分配。
  • 2017年2月至2018年3月筛查491例,随机382例。
  • 比较14天药敏指导疗法与经验性疗法。

主要发现

  • 按方案根除率:药敏指导组97.7%(250/256) vs 经验性组97.6%(81/83),P=1.00。
  • 意向性分析根除率:药敏指导组91.6%(262/286) vs 经验性组85.4%(82/96),P=0.12。
  • 药敏指导疗法未优于经验性疗法:按方案根除差异0.1%(95%CI -3.1%至3.2%),意向性分析根除差异6.2%(95%CI -0.3%至12.7%)。
  • 两种方案均有高依从性和低不良事件率。

关键数值与推荐

  • 药敏指导疗法:含艾司奥美拉唑20 mg和阿莫西林1 g每日两次,加克拉霉素500 mg、甲硝唑400 mg每日两次或左氧氟沙星500 mg每日一次(用于敏感感染),或铋剂220 mg每日两次和甲硝唑400 mg每日四次(用于三重耐药感染)。
  • 经验性疗法:含艾司奥美拉唑20 mg、铋剂220 mg每日两次、阿莫西林1 g和甲硝唑400 mg每日三次。
  • 主要结局为幽门螺杆菌根除。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing Helicobacter pylori resistance has led to decreases in treatment effectiveness. AIM: To test the effectiveness of susceptibility-guided therapy vs a locally highly effective empiric modified bismuth quadruple therapy for first-line H pylori treatment in a region with high antimicrobial resistance. METHODS: We compared 14-day susceptibility-guided with empiric therapy using a multicentre superiority-design trial, which randomised H pylori infected subjects 3:1 to (a) susceptibility-guided therapies contained esomeprazole 20 mg and amoxicillin 1 g b.d. plus clarithromycin 500 mg, metronidazole 400 mg b.d., or levofloxacin 500 mg daily for susceptible infections or bismuth 220 mg b.d. and metronidazole 400 mg q.d.s. for triple-resistant infections; (b) Empiric therapy contained esomeprazole 20 mg, bismuth 220 mg b.d., amoxicillin 1 g and metronidazole 400 mg t.d.s. Primary outcome was H pylori eradication. RESULTS: Between February 2017 and March 2018, 491 subjects were screened and 382 were randomised. Both the susceptibility-guided and the empiric regimens were highly successful with per-protocol eradication rates of 97.7% (250/256) vs 97.6% (81/83, P = 1.00) and intent-to-treat eradication rates of 91.6% (262/286) vs 85.4% (82/96, P = 0.12). Overall, susceptibility-guided therapy was not superior to empiric therapy with 0.1% per-protocol (95% CI -3.1% to 3.2%) and 6.2% intent-to-treat (-0.3% to 12.7%) eradication difference. Both approaches had high adherence and low adverse event rates. CONCLUSIONS: Both susceptibility-guided and empiric therapies provided excellent eradication rates. Clinically, the choice would hinge on availability of susceptibility testing and/or a locally highly effective empiric therapy.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chen Q, Long X, Ji Y, et al. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019. PMID: 31020673. doi:10.1111/apt.15273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。